Metabolic Reprogramming by MiRNAs in the Tumor Microenvironment: Focused on Immunometabolism

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Dec 9

PMID 36483029

Authors

Shadia Hamoud Alshahrani

Yousif Saleh Ibrahim

Abduladheem Turki Jalil

Abdelgadir Alamin Altoum

Harun Achmad

Rahman S Zabibah

Gamal A Gabr

Andres Alexis Ramirez-Coronel

Ameer A Alameri

Qutaiba A Qasim

Sajad Karampoor

Rasoul Mirzaei

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) are emerging as a significant modulator of immunity, and their abnormal expression/activity has been linked to numerous human disorders, such as cancer. It is now known that miRNAs potentially modulate the production of several metabolic processes in tumor-associated immune cells and indirectly different metabolic enzymes that affect tumor-associated signaling cascades. For instance, Let-7 has been identified as a crucial modulator for the long-lasting survival of CD8 T cells (naive phenotypes) in cancer by altering their metabolism. Furthermore, in T cells, it has been found that enhancer of zeste homolog 2 (EZH2) expression is controlled glycolytic metabolism through miRNAs in patients with ovarian cancer. On the other hand, immunometabolism has shown us that cellular metabolic reactions and processes not only generate ATP and biosynthetic intermediates but also modulate the immune system and inflammatory processes. Based on recent studies, new and encouraging approaches to cancer involving the modification of miRNAs in immune cell metabolism are currently being investigated, providing insight into promising targets for therapeutic strategies based on the pivotal role of immunometabolism in cancer. Throughout this overview, we explore and describe the significance of miRNAs in cancer and immune cell metabolism.

Citing Articles

Reactive oxygen species induced by SARS-CoV-2 infection can induce EMT in solid tumors: Potential role of COVID-19 in chemo-resistance and metastasis.

Moulaeian M, Ferdousmakan S, Banihashemi S, Homayounfar S, Pasupulla A, Malekzadegan Y Heliyon. 2024; 10(22):e40297.

PMID: 39624316 PMC: 11609686. DOI: 10.1016/j.heliyon.2024.e40297.

MicroRNA-mediated metabolic regulation of immune cells in cancer: an updated review.

Khameneh S, Razi S, Lashanizadegan R, Akbari S, Sayaf M, Haghani K Front Immunol. 2024; 15:1424909.

PMID: 39007129 PMC: 11239499. DOI: 10.3389/fimmu.2024.1424909.

Unveiling the Role of Exosomes in the Pathophysiology of Sepsis: Insights into Organ Dysfunction and Potential Biomarkers.

Gebeyehu G, Rashidiani S, Farkas B, Szabadi A, Brandt B, Pap M Int J Mol Sci. 2024; 25(9).

PMID: 38732114 PMC: 11084308. DOI: 10.3390/ijms25094898.

Immunometabolism, extracellular vesicles and cardiac injury.

Omoto A, do Carmo J, da Silva A, Hall J, Mouton A Front Endocrinol (Lausanne). 2024; 14:1331284.

PMID: 38260141 PMC: 10800986. DOI: 10.3389/fendo.2023.1331284.

Prognostic Significance of Preoperative Inflammation Markers on the Long-Term Outcomes in Peritoneal Carcinomatosis from Ovarian Cancer.

Balescu I, Eftimie M, Petrea S, Diaconu C, Gaspar B, Pop L Cancers (Basel). 2024; 16(2).

PMID: 38254745 PMC: 10814080. DOI: 10.3390/cancers16020254.

References

Semenza G . Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. DOI: 10.1038/nrc1187. View

He M, Jin Q, Chen C, Liu Y, Ye X, Jiang Y . The miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells. Oncogene. 2019; 38(28):5551-5565. DOI: 10.1038/s41388-019-0817-3. View

Munn D, Mellor A . IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. Trends Immunol. 2016; 37(3):193-207. PMC: 4916957. DOI: 10.1016/j.it.2016.01.002. View

Zhang T, Zhang Z, Li F, Ping Y, Qin G, Zhang C . miR-143 Regulates Memory T Cell Differentiation by Reprogramming T Cell Metabolism. J Immunol. 2018; 201(7):2165-2175. DOI: 10.4049/jimmunol.1800230. View

Yan Z, Shah P, Amin S, Samur M, Huang N, Wang X . Integrative analysis of gene and miRNA expression profiles with transcription factor-miRNA feed-forward loops identifies regulators in human cancers. Nucleic Acids Res. 2012; 40(17):e135. PMC: 3458521. DOI: 10.1093/nar/gks395. View

Buller C, Loberg R, Fan M, Zhu Q, Park J, Vesely E . A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. Am J Physiol Cell Physiol. 2008; 295(3):C836-43. PMC: 2544442. DOI: 10.1152/ajpcell.00554.2007. View

Chang C, Qiu J, OSullivan D, Buck M, Noguchi T, Curtis J . Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162(6):1229-41. PMC: 4864363. DOI: 10.1016/j.cell.2015.08.016. View

Gharib E, Nasrabadi P, Zali M . miR-497-5p mediates starvation-induced death in colon cancer cells by targeting acyl-CoA synthetase-5 and modulation of lipid metabolism. J Cell Physiol. 2020; 235(7-8):5570-5589. DOI: 10.1002/jcp.29488. View

Cui M, Wang Y, Sun B, Xiao Z, Ye L, Zhang X . MiR-205 modulates abnormal lipid metabolism of hepatoma cells via targeting acyl-CoA synthetase long-chain family member 1 (ACSL1) mRNA. Biochem Biophys Res Commun. 2014; 444(2):270-5. DOI: 10.1016/j.bbrc.2014.01.051. View

10.

Tsai W, Hsu S, Hsu C, Lai T, Chen S, Shen R . MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest. 2012; 122(8):2884-97. PMC: 3408747. DOI: 10.1172/JCI63455. View

11.

DeBerardinis R, Cheng T . Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene. 2009; 29(3):313-24. PMC: 2809806. DOI: 10.1038/onc.2009.358. View

12.

Zhao X, Qu J, Sun Y, Wang J, Liu X, Wang F . Prognostic significance of tumor-associated macrophages in breast cancer: a meta-analysis of the literature. Oncotarget. 2017; 8(18):30576-30586. PMC: 5444766. DOI: 10.18632/oncotarget.15736. View

13.

Kruger M, Moser M, Ussar S, Thievessen I, Luber C, Forner F . SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell. 2008; 134(2):353-64. DOI: 10.1016/j.cell.2008.05.033. View

14.

Zhu L, Zhu X, Wu Y . Effects of Glucose Metabolism, Lipid Metabolism, and Glutamine Metabolism on Tumor Microenvironment and Clinical Implications. Biomolecules. 2022; 12(4). PMC: 9028125. DOI: 10.3390/biom12040580. View

15.

Keating S, Zaiatz-Bittencourt V, Loftus R, Keane C, Brennan K, Finlay D . Metabolic Reprogramming Supports IFN-γ Production by CD56bright NK Cells. J Immunol. 2016; 196(6):2552-60. DOI: 10.4049/jimmunol.1501783. View

16.

Nagaraja A, Creighton C, Yu Z, Zhu H, Gunaratne P, Reid J . A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol. 2010; 24(2):447-63. PMC: 2817607. DOI: 10.1210/me.2009-0295. View

17.

Wei X, Tang C, Lu X, Liu R, Zhou M, He D . MiR-101 targets DUSP1 to regulate the TGF-β secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinoma. Oncotarget. 2015; 6(21):18389-405. PMC: 4621898. DOI: 10.18632/oncotarget.4089. View

18.

Zheng W, Feng Q, Liu J, Guo Y, Gao L, Li R . Inhibition of 6-phosphogluconate Dehydrogenase Reverses Cisplatin Resistance in Ovarian and Lung Cancer. Front Pharmacol. 2017; 8:421. PMC: 5491617. DOI: 10.3389/fphar.2017.00421. View

19.

He Y, Deng F, Zhao S, Zhong S, Zhao J, Wang D . Analysis of miRNA-mRNA network reveals miR-140-5p as a suppressor of breast cancer glycolysis via targeting GLUT1. Epigenomics. 2019; 11(9):1021-1036. DOI: 10.2217/epi-2019-0072. View

20.

Patra K, Hay N . The pentose phosphate pathway and cancer. Trends Biochem Sci. 2014; 39(8):347-54. PMC: 4329227. DOI: 10.1016/j.tibs.2014.06.005. View